Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck Semiconductor ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while VanEck Semiconductor ETF trades at $585.29. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SMH | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $668.91 |
52-Week Low | $12.30 | $286.43 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
SMH trades at $584.83, up 2.71% with a neutral technical signal. Moving averages show bullish momentum while oscillators indicate neutral conditions. Recent institutional activity includes Ferguson Shapiro's $4.53 million investment and Clark Asset Management's 105.8% stake increase. The ETF faces competition from alternative semiconductor funds like CHPY, which some analysts favor for income generation.
Outlook remains balanced with AI spending driving semiconductor demand but increasing competition and tariff risks. The fund's heavy Nvidia concentration presents both opportunity and volatility risk. Technical resistance at $587 could limit near-term gains while support at $560 provides downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
